Shionogi & Co Ltd - FDA Accepts Shionogi's Ensitrelvir NDA For Review As First Oral Therapy For Prevention Of Covid-19 Following Exposure
Sept 3 (Reuters) - Shionogi & Co Ltd 4507.T:
SHIONOGI & CO LTD: FDA ACCEPTS SHIONOGI'S ENSITRELVIR NDA FOR REVIEW AS FIRST ORAL THERAPY FOR PREVENTION OF COVID-19 FOLLOWING EXPOSURE
SHIONOGI & CO LTD: FDA HAS SET AN ACTION DATE OF JUNE 16, 2026 UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA)
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Robinhood Stock Predictions: Can HOOD Reach the $1,000 Milestone?

Anthropic Eclipses OpenAI in Secondary Market as Valuation Hits $1 Trillion Milestone, Is the AI Market Overheating Now?

Tesla Officially Announces. Third-Generation Humanoid Robot to Debut Mid-Year, Mass Production to Start in Third Quarter

Intel Better-Than-Expected Earnings Released, Stock Surges 20% After-Hours, AI Computing Power Enters CPU Moment?

Tradingkey








